Evidence map›Paper›PMID 32378459›Full record

ReviewNanomedicine (London, England)2020

Application of nanomaterials in treatment, anti-infection and detection of coronaviruses.

Ghazal Nikaeen, Sepideh Abbaszadeh, Saeed Yousefinejad

Open access · greenAbstract readReview
In one paragraph

Review in Nanomedicine (London, England), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 68 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
68citing papers in PubMed, 1 pooled it
3.3field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

68 citing papers in PubMed, 1 synthesis or guideline pooled it, 158 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. In Silico Analysis of CMolecules (Basel, Switzerland) · 2025
    Article
  5. Article
  6. Imaging of Viral Genomic RNA Replication with Nanoprobes.Methods in molecular biology (Clifton, N.J.) · 2025
    Article
  7. Review
  8. Review
  9. Article
  10. Review
  11. Review
  12. Article
  13. Review
  14. Review
  15. Review
  16. Review
  17. Review
  18. Review
  19. High-efficiency reduction ofRSC advances · 2022
    Article
  20. Review

8 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Ghazal NikaeenResearch Center for Health Sciences, Institute of Health, School of Health, Shiraz University of Medical Sciences, Shiraz, Iran.
Sepideh AbbaszadehResearch Center for Health Sciences, Institute of Health, School of Health, Shiraz University of Medical Sciences, Shiraz, Iran.
Saeed YousefinejadResearch Center for Health Sciences, Institute of Health, School of Health, Shiraz University of Medical Sciences, Shiraz, Iran.ORCID 0000-0001-5940-1229
Shiraz University of Medical Sciences · IR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Nanotechnology and nanomedicine have excellent potential in dealing with a range of different health problems, including viruses, which are considered to be a serious challenge in the medical field. Application of nanobiotechnology could represent a new avenue for the treatment or disinfection of viruses. There is increasing concern regarding the control of coronaviruses, among these, Middle East respiratory syndrome coronavirus, severe acute respiratory syndrome coronavirus and severe acute respiratory syndrome coronavirus-2 are well known and dangerous examples. This article aims to provide an overview of recent studies on the effectiveness of nanoparticles as diagnostic or antiviral tools against coronaviruses. The possibilities of effectively using nanomaterials as vaccines and nanosensors in this field are also presented.

Indexed as

AnimalsAntiviral AgentsBiosensing TechniquesCoronavirusCoronavirus InfectionsCOVID-19HumansNanomedicineNanoparticlesNanotechnologyPandemicsPneumonia, ViralAntiviral Agentsantiviralbio-labelingcoronavirusesCOVID-19gold nanoparticlesprotein nanoparticlessevere acute respiratory syndrome coronavirussilver nanoparticlestransmissible gastroenteritis virusvaccine nanotechnology

Identifiers

PMID32378459
PMCPMC7373208
OpenAlexW3022724310

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.